WestVac Biopharma
WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity,foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.
广州威涂士建材科技有限公司是生产经营涂料的高新技术股份制企业。公司引进先进技术以及进口原材料及设备,聚集行业专业人员,专业从事的涂料研究和开发。产品包括地坪涂料、防腐涂料、防水涂料及墙体涂料等。 威涂士的宗旨是以诚信为本,取信于民。产品致力于科研开发,创新和发展,立足于高起点高品质,以质量求生存,以信誉求发展,并一贯倡导“环保健康”,“绿色生活”的产品理念。 威涂士产品通过了ISO9001国际质量管理体系认证及ISO14001国际环境管理体系认证。以严格的管理,精心的设计,专业的施工,完善的服务为众多国内知名企业量身打造了合适的方案。一直以生产质优的材料,采用先进的施工技术,引进先进的管理水平为经营路线,施工设备先进,齐全,配有多支训练有素的专业施工队伍,可为顾客提供优良的服务,能够有效的为顾客解决各种难题,为每一个顾客提供质优满意的产品。 威涂士专注于做混凝土表面防护的处理,争做地坪漆行业的先锋,愿以自身行动来为规范和引导混凝土表面防护涂料行业的深入研究和发展做贡献。